Table 4 Effects of low dose aspirin (LDA) on the results of fecal immunochemical test in colorectal neoplasms screening.
Measure | Outcome | LDA | p-value | |
|---|---|---|---|---|
Yes (n = 71) | No (n = 614) | |||
Sensitivity | CN | 14/25 (56.0%) CI (34.9–75.6%) | 122/217 (56.0%) CI (49.3–62.9%) | 0.9832 |
CRC | 5/6 (83.3%) CI (35.9–99.6%) | 35/43 (81.4%) CI (66.6–91.6%) | 0.9086 | |
CRC + AA | 8/13 (61.5%) CI (35.9–99.6%) | 75/99 (75.8%) CI (66.1–83.8%) | 0.2370 | |
NAA only | 6/12 (50.0%) CI (21.1–99.6%) | 47/118 (39.8%) CI (30.9–49.3%) | 0.4946 | |
Specificity | CN | 26/46 (56.5%) CI (41.1–71.1%) | 223/397 (56.2%) CI (51.1–61.1%) | 0.9638 |
CRC | 36/65 (55.4%) CI (42.5–67.7%) | 310/571 (54.3%) CI (50.1–58.4%) | 0.8668 | |
CRC + AA | 32/58 (55.2%) CI (41.5–68.3%) | 294/515 (57.1%) CI (52.7–61.4%) | 0.7801 | |
NAA only | 26/46 (56.5%) CI (41.1–71.1%) | 223/397 (56.2%) CI (51.1–61.1%) | 0.9638 | |
PPV | CN | 14/34 (41.2%) CI (24.6–59.3%) | 122/296 (41.2%) CI (35.6–47.1%) | 0.9964 |
CRC | 5/34 (14.7%) CI (5.0–31.1%) | 35/296 (11.8%) CI (8.4–16.1%) | 0.6259 | |
CRC + AA | 8/34 (23.5%) CI (10.7–41.2%) | 75/296 (25.3%) CI (20.5–30.7%) | 0.8179 | |
NAA only | 6/26 (23.1%) CI (9.0–43.6%) | 47/221 (21.3%) CI (16.1–27.3%) | 0.8316 | |
NPV | CN | 26/37 (70.3%) CI (53.0–84.1%) | 223/318 (70.1%) CI (64.8–75.1%) | 0.9854 |
CRC | 36/37 (97.3%) CI (85.8–99.9%) | 310/318 (97.5%) CI (95.1–98.9%) | 0.9454 | |
CRC + AA | 32/37 (86.5%) CI (71.2–95.5%) | 294/318 (92.5%) CI (89.0–95.1%) | 0.2098 | |
NAA only | 26/32 (81.2%) CI (63.6–92.8%) | 223/294 (75.9%) CI (70.5–80.6%) | 0.4946 | |
